<DOC>
	<DOCNO>NCT00137111</DOCNO>
	<brief_summary>The primary objective estimate overall event-free survival child least one year age diagnosis treat risk-directed therapy monitor molecular remission induction rate .</brief_summary>
	<brief_title>Therapy Newly Diagnosed Patients With Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>These follow secondary objective : - To determine CNS irradiation safely omit context systemic therapy use protocol . - To identify whether prolonged ( 24 hour ) intravenous infusion HDMTX produce great methotrexate polyglutamate ( MTXPG ) accumulation short ( 4 hour ) infusions 42 hour 1 gm/m2 HDMTX , stratify lineage ( T- v B-lineage ) ploidy ( hyperdiploid v non-hyperdiploid B-lineage ) . - To determine whether prolonged ( 24 hour ) intravenous infusion HDMTX produce great antileukemic effect short ( 4 hour ) infusion , base inhibition de novo purine synthesis bone marrow blast decrease circulate blast 4 day `` window '' prior initiation conventional remission induction therapy . - MRD - Other exploratory objective Details Treatment Plan Treatment consist three main phase , Remission Induction , Consolidation , Continuation . Treatment Upfront HDMTX Window research purpose optional . All patient receive IT therapy day 1 , dose age dependent . Upfront High-Dose Methotrexate Window HDMTX ( 1 g/m2 ) 4 hour infusion versus 24 hour infusion . Leucovorin rescue give . Remission Induction Prednisone 40 mg/m2/day PO Days 5 - 32 Vincristine 1.5 mg/m2/week IV Days 5 , 12 , 19 , 26 Daunorubicin 25 mg/m2/week IV Days 5 , 12 L-asparaginase 10,000 Unit/m2/dose IM Days 6 , 8 , 10 , 12 , 14 , 16 ( 19 , 21 , 23 ) Cyclophosphamide 1000 mg/m2/dose IV Day 26 Cytarabine 75 mg/m2/dose IV Days 27-30 , 34-37 6-Mercaptopurine 60 mg/m2/dose PO Days 26-39 Imatinib 40 mg/m2 bid Ph positive patient start Day 22 induction . Intrathecal therapy administer day 1 19 , dose age dependent . Patients high risk CNS relapse receive additional IT treatments day 8 26 . Consolidation Treatment High dose methotrexate target dose depend risk status , day 1 , 15 , 29 , 43 mercaptopurine 50 mg/m2/day , day 1-56 . Reintensification treatment patient high risk disease : Patients high risk disease offer option hematopoietic stem cell transplant ( HSCT ) may receive additional 1-2 cycle reintensification treatment prior maximize anti-leukemic kill transplant . Dexamethasone 20 mg/m2 PO day 1-3 Cytarabine 2 g/m2 IV x 4 dos , day 3-5 Etoposide 100 mg/m2 IV x 5 dos , day 3-5 L-asparaginase 25,000 Units/m2 IM day 6 Intrathecal treatment Day 5 Continuation Treatment ( last 120 week girls 146 week boys ) Treatment depend risk classification : low versus standard versus high risk Treatment week 1 20 : Week Standard/High Risk Low Risk 1 . DEX + DOX + VCR + 6MP + ASP 6MP + DEX + VCR 2 . 6MP + ASP 6MP + MTX 3 . 6MP + ASP 6MP + MTX 4 . DEX + DOX + VCR + 6MP + ASP 6MP + DEX + VCR 5 . 6MP + ASP 6MP + MTX 6 . 6MP + ASP 6MP + MTX 7 . Reinduction I§ Reinduction I 8 . Reinduction I Reinduction I 9 . Reinduction I Reinduction I 10 . 6MP + ASP 6MP + MTX 11 . DOX + VCR + 6MP + ASP 6MP + MTX 12 . 6MP + ASP 6MP + MTX 13 . 6MP + ASP 6MP + MTX 14 . DEX + DOX + VCR + 6MP + ASP 6MP + DEX + VCR 15 . 6MP + ASP 6MP + MTX 16 . 6MP + ASP 6MP + MTX 17 . Reinduction II Reinduction II 18 . Reinduction II Reinduction II 19 . Reinduction II Reinduction II 20 . No chemotherapy 6MP + MTX Dexamethasone 12 mg/m2 ( std/high risk ) 8 mg/m2 ( low risk ) PO daily ( tid ) x 5 day , Days 1-5 Doxorubicin 30 mg/m2 IV , Day 1 Vincristine 2.0 mg/m2 IV push ( max . 2 mg ) , Day 1 Mercaptopurine 50 mg/m2 PO daily x 7 day ( std/high risk ) , Days 1-7 75 mg/m2 PO daily x 7 day ( low risk ) , Days 1-7 L-asparaginase 25,000 Unit/m2 IM , Day 1 Methotrexate 40 mg/m2 IV IM , Day 1 Reinduction I II This phase treatment start week 7 17 bone marrow examination confirm complete remission . Reinduction treatment give twice : week 7 9 week 17 19 patient . Reinduction I Standard/High Risk ALL : Dexamethasone 8 mg/m2/day PO ( t.i.d . ) Days 1-8 , 15 , 21 , Vincristine 1.5 mg/m2/week IV ( max 2 mg ) Days 1 , 8 , 15 , Doxorubicin 30 mg/m2 Days 1 , 8 , L-asparaginase 25,000 Unit/m2 IM Days 1 , 8 , 15 , Intrathecal chemotherapy , dose age dependent Day 1 . Reinduction II Standard/High Risk ALL : Dexamethasone 8 mg/m2/day PO ( t.i.d . ) Days 1-8 , 15-21 , Vincristine 1.5 mg/m2/week IV ( max 2 mg ) Days 1 , 8 , 15 , L-asparaginase 25,000 Unit/m2 , weekly IM Days 1 , 8 , 17 , Intrathecal chemotherapy , dose age dependent Day 1 High-dose cytarabine 2 gm/m2 IV q 12 Days 15 , 16 Reinduction I II Low Risk ALL Dexamethasone 8 mg/m2/day PO ( t.i.d . ) Days 1-8 , 15-21 Vincristine 1.5 mg/m2/week IV ( max 2 mg ) , Days 1 , 8 , 15 L-asparaginase 10,000 Unit/m2/thrice weekly IM Days 2 , 4 , 6 , 8 , 10 , 12 , 15 , 17 , 19 Doxorubicin 30 mg/m2/week IV Day 1 Intrathecal chemotherapy , dose age dependent Day 1 Treatment Weeks 21 end therapy Week Standard/High Risk Low Risk 21 . 6MP + MTX 6MP + MTX 22 . 6MP + MTX 6MP + MTX 23 . Cyclo + Ara-C 6MP + MTX 24 . DEX + VCR 6MP + DEX + VCR 25 . 6MP + MTX 6MP + MTX 26 . 6MP + MTX 6MP + MTX 27 . Cyclo + Ara-C 6MP + MTX 28 . DEX + VCR 6MP + DEX + VCR Mercaptopurine 75 mg/m2 PO , daily x 7 day , Days 1-7 Methotrexate 40 mg/m2 IV IM , Day 1 Cyclophosphamide 300 mg/m2 IV , Day 1 Cytarabine 300 mg/m2 IV , Day 1 Dexamethasone 12 mg/m2 ( std/high risk ) 8 mg/m2 ( low risk ) PO daily ( tid ) x 5 , Day 1-5 Vincristine 2.0 mg/m2 IV push ( max . 2 mg ) , Day 1 The treatment ( week 21-28 ) repeat total 6 time ( week 68 ) . After week 68 , patient receive daily 6MP weekly MTX pulse dexamethasone vincristine every 4 week week 100 , 6MP methotrexate give . Intrathecal treatment give every 8 week patient high risk CNS relapse week 48 discontinue week 96 . Continuation therapy discontinue 120 week girls 146 week boys Patients meet criterion high-risk ALL candidate allogeneic hematopoietic stem cell transplantation . However , option decline patient guardian , procedure deem unsuitable attend physician principal investigator , patient remain study continue receive chemotherapy</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Diagnosis nonBcell ALL immunophenotyping , determine reactivity pattern panel monoclonal antibody flow cytometry well morphology cytochemical staining . Age range : 1 18 year ( inclusive ) . • Previously treat chemotherapy one week longer .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Leukemia</keyword>
</DOC>